Association of the 3050G>C Polymorphism in the Cyclooxygenase 2 Gene with Systemic Sarcoidosis

Archives of Medical Research

Volumn 39, Issue 5, 2008, Pages 525-530

  Lopez Campos, José Luis ^a   Rodriguez Rodriguez, D ^a   Rodriguez Becerra, E ^a   Michavila, I Alfageme ^b   Guerra, J Fernandez ^c   Hernandez, F J García ^a   Casanova, A ^d   de Córdoba Gamero, J Fernández ^e   Ortiz, A Romero ^f   Arellano Orden, E ^a   Montes Worboys, A ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^c HOSPITAL COSTA DEL SOL   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Clinical presentation; Cyclooxygenase 2; Polymorphisms; Sarcoidosis

Indexed keywords

CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE;

ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL LYMPHOCYTE; SARCOIDOSIS; SPAIN;

CYCLOOXYGENASE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SARCOIDOSIS;

EID: 44249084153     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2008.03.004     Document Type: Article

References (30)

1. Statement on sarcoidosis. Am J Respir Crit Care Med 160 (1999) 736-755
2. Henke C.E., Henke G., Elveback L.R., Beard C.M., Ballard D.J., and Kurland L.T. The epidemiology of sarcoidosis in Rochester, Minnesota: a population-based study of incidence and survival. Am J Epidemiol 123 (1986) 840-845
3. Fernandez Fabrellas E. Epidemiología de la sarcoidosis. Arch Bronconeumol 43 (2007) 92-100
4. López-Campos J.L., Rodríguez-Becerra E., and Neumosur Task Group. Registry of Interstitial Lung Diseases. Incidence of interstitial lung diseases in the south of Spain 1998-2000: the RENIA study. Eur J Epidemiol 19 (2004) 155-161
5. Costabel U. CD4/CD8 ratios in bronchoalveolar lavage fluid: of value for diagnosing sarcoidosis?. Eur Respir J 10 (1997) 2699-2700
6. Wiegand J.A., and Brutsche M.H. Sarcoidosis is a multisystem disorder with variable prognosis-information for treating physicians. Swiss Med Wkly 136 (2006) 203-209
7. Subramanian P., Chinthalapalli H., Krishnan M., Tarlo S.M., Lobbedez T., Pineda M.E., et al. Pregnancy and sarcoidosis: an insight into the pathogenesis of hypercalciuria. Chest 126 (2004) 995-998
8. Korn J.H. Fibroblast prostaglandin E2 synthesis. Persistence of an abnormal phenotype after short-term exposure to mononuclear cell products. J Clin Invest 71 (1983) 1240-1246
9. Hempel S.L., Monick M.M., and Hunninghake G.W. Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J Clin Invest 93 (1994) 391-396
10. Wilborn J., Crofford L.J., Burdick M.D., Kunkel S.L., Strieter R.M., and Peters-Golden M. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 95 (1995) 1861-1868
11. Pang L., Pitt A., Petkova D., and Knox A.J. The COX-1/COX-2 balance in asthma. Clin Exp Allergy 28 (1998) 1050-1058
12. Petkova D.K., Clelland C.A., Ronan J.E., Lewis S., and Knox A.J. Reduced expression of cyclooxygenase (COX) in idiopathic pulmonary fibrosis and sarcoidosis. Histopathology 43 (2003) 381-386
13. Costabel U. Sensitivity and specificity of BAL findings in sarcoidosis. Sarcoidosis 9 (1992) 211-214
14. Siltzbach L.E., James D.G., Neville E., Turiaf J., Battesti J.P., Sharma O.P., et al. Course and prognosis of sarcoidosis around the world. Am J Med 57 (1974) 847-852
15. th ed (1994), Panamericana, Buenos Aires 27-46
16. Skarke C., Schuss P., Kirchhof A., Doehring A., Geisslinger G., and Lötsch J. Pyrosequencing of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance. Pharmacogenomics 8 (2007) 1643-1660
17. Bernard P.B., and Witter C.T. Homogenous amplification and variant detection by fluorescent hybridization probes by fluorescent hybridization probes. Clin Chem 46 (2000) 147-148
18. Nagai S., and Izumi T. Pulmonary sarcoidosis: population differences and pathophysiology. South Med J 88 (1995) 1001-1010
19. Mrazek F., Holla L.I., Hutyrova B., Znojil V., Vasku A., Kolek V., et al. Association of tumour necrosis factor-alpha, lymphotoxin-alpha and HLA-DRB1 gene polymorphisms with Lofgren's syndrome in Czech patients with sarcoidosis. Tissue Antigens 65 (2005) 163-171
20. Spagnolo P., Sato H., Marshall S.E., Antoniou K.M., Ahmad T., Wells A.U., et al. Association between heat shock protein 70/Hom genetic polymorphisms and uveitis in patients with sarcoidosis. Invest Ophthalmol Vis Sci 48 (2007) 3019-3025
21. Hizawa N., Yamaguchi E., Furuya K., Jinushi E., Ito A., and Kawakami Y. The role of the C-C chemokine receptor 2 gene polymorphism V64I (CCR2-64I) in sarcoidosis in a Japanese population. Am J Respir Crit Care Med 159 (1999) 2021-2023
22. Furuya K., Yamaguchi E., and Kawakami Y. Angiotensin-converting enzyme (ACE) polymorphism and serum ACE activities in sarcoidosis. Nippon Rinsho 52 (1994) 1561-1566
23. Spagnolo P., Sato H., Grutters J.C., Renzoni E.A., Marshall S.E., Ruven H.J., et al. Analysis of BTNL2 genetic polymorphisms in British and Dutch patients with sarcoidosis. Tissue Antigens 70 (2007) 219-227
24. Cox D.G., Buring J., Hankinson S.E., and Hunter D.J. A polymorphism in the 3′ untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study. Breast Cancer Res 9 (2007) R3
25. Cox D.G., Crusius J.B.A., Peeters P.H.M., Bueno-de-Mesquita H.B., Salvador Peña A., and Canzian F. A haplotype of prostaglandin synthase 2/cyclooxygenase 2 is involved in the susceptibility to inflammatory bowel disease. World J Gastroenterol 11 (2005) 6003-6008
26. Wolter N.J., Kunkel S.L., Lynch III J.P., and Ward P.A. Production of cyclooxygenase products by alveolar macrophages in pulmonary sarcoidosis. Chest 83 (1983) 79S-81S
27. Hill M.R., Papafili A., Booth H., Lawson P., Hubner M., Beynon H., et al. Functional prostaglandin-endoperoxide synthase 2 polymorphism predicts poor outcome in sarcoidosis. Am J Respir Crit Care Med 174 (2006) 915-922
28. Stenson W.F., and Parker C.W. Prostaglandins, macrophages, and immunity. J Immunol 125 (1980) 1-5
29. Lama V., Moore B.B., Christensen P., Toews G.B., and Peters-Golden M. Prostaglandin E2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent. Am J Respir Cell Mol Biol 27 (2002) 752-758
30. Willoughby D.A., Moore A.R., and Colville-Nash P.R. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet 355 (2000) 646-648